{
    "Trade/Device Name(s)": [
        "Access Testosterone",
        "Access Testosterone Assay"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K223405",
    "Predicate Device Reference 510(k) Number(s)": [
        "K001935"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "January 13, 2023",
    "Summary Letter Received Date": "November 9, 2022",
    "Submission Date": "November 7, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle assay",
        "Competitive binding immunoenzymatic assay"
    ],
    "Methodologies": [
        "Automated immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent Pack",
        "Buffer",
        "Substrate"
    ],
    "Document Summary": "FDA 510(k) summary for Access Testosterone chemiluminescent immunoassay for quantitative testosterone determination in serum and plasma on Access Immunoassay Systems",
    "Indications for Use Summary": "Quantitative determination of total testosterone in human serum and plasma to aid in diagnosing and treating disorders involving male sex hormones and androgen-related conditions",
    "fda_folder": "Clinical Chemistry"
}